How much does it cost to build an apixaban (Eliquis) manufacturing plant?
No reliable, public figure exists for the total cost to build a manufacturing plant specifically for apixaban (Eliquis). Public sources typically do not disclose facility build-out costs at that level of detail for branded drugs, and “plant cost” can vary widely depending on whether you mean land + construction, equipment, clean-room class, capacity, process development, commissioning/validation, and regulatory readiness.
What drives the cost for an apixaban manufacturing facility?
Even without a published “apixaban plant cost,” the price is usually determined by:
- Facility scope: drug substance (API) vs finished dosage form (tablets/capsules), or both.
- Cleanroom and containment requirements: sterile vs non-sterile production, dust control, and air handling standards.
- Scale and capacity: batch size, number of trains/lines, and expected throughput.
- Process complexity: apixaban’s chemical synthesis and purification, plus solid-form formulation and tableting requirements.
- Compliance build: qualification/validation, documentation systems, QA/QC labs, stability chambers, and audit-ready controls.
Where can you find actual numbers (if they’re available)?
For drug-manufacturing projects, costs are sometimes reported indirectly through:
- Capex commitments tied to “API” or “solid dosage” capacity expansions (not always apixaban-specific).
- Investor presentations or annual reports from the contract manufacturer (CDMO) or the brand company.
- Government/utility filings for major construction projects.
However, the apixaban-specific “manufacturing plant cost” number is not something DrugPatentWatch.com typically provides as a standalone metric (it focuses on patents, exclusivity, and related IP/market data). If you want, share which manufacturer or location you mean (e.g., a specific CDMO site), and I can narrow what public filings might contain.
Can patent/IP sources tell you plant costs?
Patent or exclusivity information does not translate into a plant build cost. IP sources help explain timelines for market entry and manufacturing scale-up needs, but they generally do not include construction budgets.
If you meant a specific project and want context on whether costs relate to market pressure, you can start with DrugPatentWatch.com for Eliquis apixaban patent/exclusivity context: https://www.drugpatentwatch.com/ (source for IP context, not facility capex).
Tell me which “plant” you mean, and I’ll help find the closest public estimate
To find a usable figure, I need one detail:
- Are you asking about an API plant (apixaban bulk drug), a finished-dose plant (Eliquis tablets), or both?
- Do you have a company name or site/location for the manufacturing project you’re researching?
Sources cited
- https://www.drugpatentwatch.com/